MPM BioVentures 2014, L.P.
CIK 1609492 · last filed 2026-09-09
MPM BioVentures 2014, L.P. is a corporate insider who has filed 23 SEC Form 4 insider transactions across 4 companies since 2019. The most recent filing shows the insider sold $19.1M of TRDA on Sep 9, 2026. Across all open-market trades the lifetime net is +$95.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $23.4M across reported positions. The firm reports its address in Boston, MA. 59 SEC filings were submitted jointly with MPM Asset Management Investors BV2014 LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TCRR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
399 BOYLSTON STREET, SUITE 1100
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TRDA | 10%+ Owner | 3,913,952 | $4.75 | $18.59M | -$19.06M | 1 | 2026-09-09 |
| HOWL | 4,867,341 | $0.98 | $4.77M | -$916.4K | 1 | 2025-12-04 | |
| iTeos Therapeutics, Inc. (ITOS) Delisted | 10%+ Owner | 69,951 | $10.15 | $710.0K | $30.40M | 1 | 2020-07-29 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | 10%+ Owner | 3,021,298 | $1.48 | $4.47M | $84.80M | 1 | 2019-02-21 |
Recent Filings
23 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-09 | TRDA | Sell (S) | −2,598,370 | -$19.06M | EDGAR |
| 2026-07-06 | HOWL | Notice (144) | −96,873 | -$33.0K | EDGAR |
| 2026-06-29 | HOWL | Notice (144) | −106,262 | -$34.3K | EDGAR |
| 2026-05-28 | HOWL | Notice (144) | −244,185 | -$119.7K | EDGAR |
| 2026-05-18 | HOWL | Notice (144) | −290,419 | -$149.6K | EDGAR |
| 2026-05-11 | HOWL | Notice (144) | −84,491 | -$57.5K | EDGAR |
| 2026-05-01 | HOWL | Notice (144) | −363,593 | -$261.6K | EDGAR |
| 2026-04-29 | HOWL | Notice (144) | −130,115 | -$96.3K | EDGAR |
| 2026-04-27 | HOWL | Notice (144) | −130,115 | -$105.8K | EDGAR |
| 2026-01-06 | HOWL | Notice (144) | −198,739 | -$128.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.